Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the promise of blood-based biomarkers for treatment monitoring. Data has been presented on plasma phosphorylated-tau 217 (p-tau217) as a method to monitor the effects of lecanemab and donanemab. This research is investigating if medication discontinuation is feasible if p-tau217 is reduced to a certain level. However, further research is needed to address several questions within this area. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Suzanne Schindler reports the following disclosures: scientific advisory board for Eisai.